EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer

Hope S Rugo iD, Christine L Crossno, Yaron B Gesthalter, Kristen Kelley iD, Heather B Moore iD, Mothaffar F Rimawi iD, Kelly E Westbrook iD, Saundra S Buys iD

JCO Oncology Practice · 2023-08 · 19 (8) · 539-546

DOI: 10.1200/op.22.00480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2023-08. Verfasst von Hope S Rugo und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Lung Diseases, Interstitial, Pneumonia. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab deruxtecan (T-DXd) is an antibody drug conjugate with a topoisomerase I payload that targets the human epidermal growth factor receptor 2 (HER2). T-DXd is approved for patients with previously treated HER2-positive or HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/ISH−) metastatic/unresectable breast cancer (BC). In a second-line HER2-positive metastatic BC (mBC) population (DESTINY-Breast03 [ClinicalTrials.gov identifier: NCT03529110 ]), T-DXd demonstrated significantly improved progression-free survival (PFS) over ado-trastuzumab emtansine (12-month rate: 75.8% v 34.1%; hazard ratio, 0.28; P < .001), and in patients with HER2-low mBC treated with one prior line of chemotherapy (DESTINY-Breast04 [ClinicalTrials.gov identifier: NCT03734029 ]), T-DXd demonstrated significantly longer PFS and overall survival than physician's choice chemotherapy (10.1 v 5.4 months; hazard ratio, 0.51; P < .001, and 23.4 v 16.8 months; hazard ratio, 0.64; P < .001, respectively). Interstitial lung disease (ILD) is an umbrella term used for a group of diseases characterized by lung injury including pneumonitis, which can lead to irreversible lung fibrosis. ILD is a well-described adverse event associated with certain anticancer therapies, including T-DXd. An important part of T-DXd therapy for mBC consists of monitoring for and managing ILD. Although information on ILD management strategies is included in the prescribing information, additional information on patient selection, monitoring, and treatment can be beneficial in routine clinical practice. The objective of this review is to describe real-world, multidisciplinary clinical practices and institutional protocols used for patient selection/screening, monitoring, and management related to T-DXd–associated ILD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesLung Diseases, InterstitialPneumoniaHumansFemaleAntibodies, Monoclonal, HumanizedCamptothecinTrastuzumabErb-b2 Receptor Tyrosine Kinases

Substanzen

Antibodies, Monoclonal, HumanizedImmunoconjugatestrastuzumab deruxtecanCamptothecinTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
  • Duke University Health System, Durham, NC.
  • Baylor College of Medicine, Houston, TX.

ORCID-Profile: Hope S Rugo, Kristen Kelley, Heather B Moore, Mothaffar F Rimawi, Kelly E Westbrook, Saundra S Buys

Zitieren

APA

Rugo, H. S., Crossno, C. L., Gesthalter, Y. B., Kelley, K., Moore, H. B., Rimawi, M. F., Westbrook, K. E., & Buys, S. S. (2023). Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer. JCO Oncology Practice, 19(8), 539-546. https://doi.org/10.1200/op.22.00480

Vancouver

Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, et al. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer. JCO Oncology Practice. 2023;19(8):539-546. doi:10.1200/op.22.00480

BibTeX
@article{Rugo2023,
  author = {Rugo, Hope S and Crossno, Christine L and Gesthalter, Yaron B and Kelley, Kristen and Moore, Heather B and Rimawi, Mothaffar F and Westbrook, Kelly E and Buys, Saundra S},
  title = {Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer},
  journal = {JCO Oncology Practice},
  year = {2023},
  volume = {19},
  number = {8},
  pages = {539--546},
  doi = {10.1200/op.22.00480}
}
Kostenlos starten →